171 related articles for article (PubMed ID: 38377118)
1. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
Uotani K; Tazawa H; Hasei J; Fujiwara T; Yoshida A; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Kondo H; Morita T; Kiyono M; Yokoo S; Hata T; Kunisada T; Takeda K; Urata Y; Fujiwara T; Ozaki T
PLoS One; 2024; 19(2):e0298292. PubMed ID: 38377118
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
3. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583
[TBL] [Abstract][Full Text] [Related]
4. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas.
Sasaki T; Tazawa H; Hasei J; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Uno F; Kagawa S; Morimoto Y; Urata Y; Ozaki T; Fujiwara T
Clin Cancer Res; 2011 Apr; 17(7):1828-38. PubMed ID: 21325287
[TBL] [Abstract][Full Text] [Related]
6. A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus.
Sasaki T; Tazawa H; Hasei J; Osaki S; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Kagawa S; Uno F; Urata Y; Ozaki T; Fujiwara T
Gene Ther; 2013 Jan; 20(1):112-8. PubMed ID: 22241176
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
9. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
Fujiwara T; Tanaka N
Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
[TBL] [Abstract][Full Text] [Related]
10. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Tanaka N
Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
[TBL] [Abstract][Full Text] [Related]
11. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.
Hashimoto Y; Tazawa H; Teraishi F; Kojima T; Watanabe Y; Uno F; Yano S; Urata Y; Kagawa S; Fujiwara T
PLoS One; 2012; 7(6):e39292. PubMed ID: 22720091
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.
Fujiwara T; Shirakawa Y; Kagawa S
Expert Rev Anticancer Ther; 2011 Apr; 11(4):525-32. PubMed ID: 21504319
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Fujiwara T; Kagawa S; Kishimoto H; Endo Y; Hioki M; Ikeda Y; Sakai R; Urata Y; Tanaka N; Fujiwara T
Int J Cancer; 2006 Jul; 119(2):432-40. PubMed ID: 16477640
[TBL] [Abstract][Full Text] [Related]
15. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
Kishimoto H; Urata Y; Tanaka N; Fujiwara T; Hoffman RM
Mol Cancer Ther; 2009 Nov; 8(11):3001-8. PubMed ID: 19887549
[TBL] [Abstract][Full Text] [Related]
16. [Oncolytic virotherapy for human solid tumors].
Fujiwara T
Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
[TBL] [Abstract][Full Text] [Related]
17. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).
Ouchi M; Kawamura H; Urata Y; Fujiwara T
Invest New Drugs; 2009 Jun; 27(3):241-5. PubMed ID: 18754077
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
Fujiwara T; Urata Y; Tanaka N
Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma.
Yano S; Miwa S; Kishimoto H; Uehara F; Tazawa H; Toneri M; Hiroshima Y; Yamamoto M; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Oncotarget; 2015 May; 6(15):13133-48. PubMed ID: 26033451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]